Dr. Gustavo A. Cadavid, MD

Dr. Cadavid practices at Oncology and Radiation Associates PA in Hialeah, Florida.

Dr. Cadavid's NPI, 1518256957, was assigned on April 6, 2011. Dr. Cadavid graduated from University of Caldas Faculty of Medicine in 1990. Dr. Cadavid holds Florida license ME 114763.

Dr. Cadavid's primary practice is Oncology and Radiation Associates PA, at 7150 W 20th Ave, Hialeah, FL 33016 in Miami-Dade County. The practice phone is (305) 436-1036.

Dr. Cadavid's primary practice is Oncology and Radiation Associates PA in Hialeah, Florida. Dr. Cadavid is also affiliated with Palmetto General Hospital. The medical group on file is Oncology and Radiation Associates PA. Dmand AI also links Dr. Cadavid to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cadavid practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Cadavid's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Cadavid is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Cadavid's licenses on file in 3 states: Florida, New Jersey and New York.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and purpura and thrombocytopenia among the conditions Dr. Cadavid treats.

CMS data shows 23,567 Medicare services from Dr. Cadavid across 10 procedure codes in 2024, for 138 Medicare patients. Medicare paid $86,612 for them. Every service was in an office.

CMS counts 138 Medicare patients who saw Dr. Cadavid in 2024. The largest group is 75 to 84, with 50 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 79% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cadavid's median patient age at 65, with 69% women.

In 2024, Dr. Cadavid wrote 2,388 Medicare Part D claims for 418 patients. 72% of them were for generic drugs. CMS names the drug for 2,183 of them, across 43 drugs with 11 or more claims each, at $7,377,235 in total drug cost. In 2023, CMS named 1,941 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Cadavid for performance year 2024, reported as part of a group. Dr. Cadavid accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cadavid as offering telehealth.

Dmand AI links 3 papers to Dr. Cadavid in 2012. 2012 was the busiest year, with 2. Dr. Cadavid's most frequent co-authors are Thomas Joseph Forlenza, MD, Gurpreet Singh Lamba, MBBS and Uzoma Nwakuche, MD.

CMS Open Payments shows 580 general payments to Dr. Cadavid from 66 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,095.

Dr. Cadavid graduated from University of Caldas Faculty of Medicine in 1990.

Dr. Cadavid is in network with 13 carriers, including United Healthcare, Cigna and HCSC. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.